<DOC>
	<DOCNO>NCT03017846</DOCNO>
	<brief_summary>Cantharidin cite dermatology pediatric literature valuable treatment option . Treatment often available private practice office , prescribe physician may offer non-FDA approved treatment individualize basis . The situation different many hospital academic setting , example , formulary define FDA-approved indication . The absence indication precludes addition many hospital formulary , thus limit option available prescribe physician deny patient access treatment offer private practice set . An indication formulary status require control clinical trial safety efficacy cantharidin MC . The objective trial see commercially-viable cantharidin formulation comparable safety efficacy profile formulation previously study condition closely match historically do clinic .</brief_summary>
	<brief_title>Safety Efficacy Topical Cantharidin Treatment Molluscum Contagiosum , Phase 2</brief_title>
	<detailed_description />
	<mesh_term>Molluscum Contagiosum</mesh_term>
	<mesh_term>Cantharidin</mesh_term>
	<criteria>Diagnosis MC Principal Investigator . Maximum 50 lesion location include face , trunk , back , leave right arm , leave right leg , hand , foot , buttock , groin . Execution Informed Consent assent form Patients immunosuppression , include organ transplantation , HIV infection . Patients utilize immunosuppressive agent ( include oral corticosteroid ) exclude except patient use inhaled corticosteroid , utilized asthma allergic rhinitis . Females reach menarche sexually active well pregnant patient excluded effect drug evaluate pregnancy . Patients great 50 MC lesion also exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>